Item 7.01 Regulation FD Disclosure.

Syneos Health, Inc. (the "Company") continually reviews and evaluates strategic business opportunities with a focus on enhancing stockholder value. At this time, the Company is not engaged in discussions with respect to, or activities in furtherance of, a potential business combination or transaction with Laboratory Corporation of America Holdings or any of its businesses or divisions.

The information in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this Current Report on Form 8-K are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's ongoing evaluation of strategic business opportunities. Actual results may differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to, changes in business conditions and other risk factors set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and other SEC filings, copies of which are available free of charge on the Company's website at investor.syneoshealth.com. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses